Latest Headlines

Latest Headlines

AstraZeneca's once-lauded drug flunks a Phase III eye cancer trial

AstraZeneca's cancer treatment selumetinib failed to significantly prolong survival in a study on melanoma that has spread to the eye, a late-stage setback for a drug once considered a bright spot in the company's oncology pipeline.

AstraZeneca ponies up for heart-attack patients with new Vida Health app

AstraZeneca is pledging its pocketbook in a new health-coaching push for heart attack patients. The partnership with Vida Health, via an app dubbed "Day by Day," puts cardiac rehab patients in touch with coaches to encourage them to adopt a healthy diet, take their meds, manage stress and stick to their exercise prescriptions.

Top 10 pharma companies in social media

Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....

GSK, Pfizer, AstraZeneca collaborations tilt U.K. academics to Big Pharma

Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.

AstraZeneca, Ironwood score PhIII success in China

AstraZeneca and Ironwood Pharmaceuticals say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints.

Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz

Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.

Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis

AstraZeneca CEO Pascal Soriot made it clear back in early 2014 that he planned to spin off a big chunk of the company's anti-infectives pipeline along with the neurosciences side of R&D. And now more than a year later the pharma company has completed the task, hatcheting down a once large group of researchers and birthing a small biotech with its own pipeline of antibiotics and a core group of investigators.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Another AZ exec jumps ship for CEO job at smaller drugmaker

AstraZeneca has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline and Novartis.

AstraZeneca nabs top pharma ad award at Cannes amid slim product-specific field

AstraZeneca and its agency DigitasLBI won the top award for pharma at the Cannes' Lions Health awards, for its disease awareness campaign "Take it From a Fish" about the importance of triglycerides. It was the first time a top award was given in pharma, as last year's judges did not select a Pharma Grand Prix winner.